Working… Menu

Pediatric Boot Camp Program

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05066893
Recruitment Status : Recruiting
First Posted : October 4, 2021
Last Update Posted : October 4, 2021
Information provided by (Responsible Party):
Georgetown University

Brief Summary:
An intensive 13 weeks program that aims to improve glucose control in children with type 1 diabetes.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Children, Only Other: telehealth visits Not Applicable

Detailed Description:

Our new PeDi-BoCa Program aims to help children with type 1 diabetes achieve better diabetes control by interacting weekly with their doctor/nurse practitioner (NP) and also by using a "smart pen" that can facilitate the burden of daily calculations with the use of an app on the phone.

Your child's doctor/NP will be able to remotely monitor your child's glucose every week (Dexcom) and make recommendations for changes, discuss solutions to possible obstacles and offer intensive diabetes education.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Type 1 Diabetes Boot Camp Program: An Intensive Program to Improve Glycemic Control in Adolescents With Type 1 Diabetes
Actual Study Start Date : November 5, 2020
Estimated Primary Completion Date : November 5, 2023
Estimated Study Completion Date : November 5, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Active Comparator: standard of care
standard of care will be given as per usual care
Other: telehealth visits
intensive visits with doctor

Experimental: intensive monitoring
intensive monitoring every week will be given to participants
Other: telehealth visits
intensive visits with doctor

Primary Outcome Measures :
  1. Change in HbA1c [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   11 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 11-18 years old
  2. HbA1c > 8.5%
  3. Duration of type 1 diabetes >1 year
  4. Child uses Dexcom and has a phone that is compatible with the InPen app and Dexcom Clarity app.

Exclusion Criteria:

Not able to attend telehealth visits

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05066893

Layout table for location information
United States, District of Columbia
Medstar Pediatrics Recruiting
Washington, District of Columbia, United States, 20007
Contact: Barbara Runner    202-243-3560 ext 5   
Principal Investigator: Evgenia Gourgari, MD         
Sponsors and Collaborators
Georgetown University
Layout table for additonal information
Responsible Party: Georgetown University Identifier: NCT05066893    
Other Study ID Numbers: 2604
First Posted: October 4, 2021    Key Record Dates
Last Update Posted: October 4, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases